Dec 6 2024 |
Healthcare Regulatory Update: DEA Extends Pandemic-Era Telehealth Prescribing Flexibilities Through 2025 |
Nelson Mullins |
Dec 6 2024 |
CRS Updates Report on Gene-Edited Plants: Regulation and Issues for Congress |
Bergeson & Campbell, P.C. |
Dec 5 2024 |
District Court Approves Consent Decrees Establishing Deadlines for Completing TSCA Risk Evaluations |
Bergeson & Campbell, P.C. |
Dec 5 2024 |
FDA Releases Long-Anticipated Guidance on Predetermined Change Control Plans for Devices That Utilize AI/ML Software |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 5 2024 |
Goin’ Down South: How the Southeastern U.S. Became the Current Hotbed of Cannabis Activity |
Bradley Arant Boult Cummings LLP |
Dec 5 2024 |
District Court Grants Summary Judgment in Part to Plaintiffs, Vacating and Remanding Final SECURE Rule to USDA |
Bergeson & Campbell, P.C. |
Dec 4 2024 |
Overcoming Patent Challenges for AI/ML-Assisted Life Sciences (TechBio) Inventions: Strategies for Navigating Section 101 at the US Patent & Trademark Office |
Mintz |
Dec 4 2024 |
O-H-N-O: Big Trouble in Little Columbus? |
Bradley Arant Boult Cummings LLP |
Dec 4 2024 |
Telehealth Update: DEA/HHS Temporary Rule, Medicare Coverage of Telehealth Services, Potential for Increased Oversight, and What to Watch For in 2025 |
Mintz |
Dec 4 2024 |
Members of Congress Urge FDA to Ban Red 3 |
Keller and Heckman LLP |
Dec 4 2024 |
This Week in 340B: November 19 – December 2, 2024 |
McDermott Will & Emery |
Dec 3 2024 |
Supplement to the 2022 Food Code |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 3 2024 |
CIPL Responds to DOJ NPRM on Bulk Transfers of Americans’ Sensitive Personal Data |
Hunton Andrews Kurth |
Dec 3 2024 |
FDA Issues Draft Guidance on Infant Formula Manufacture Discontinuance or Disruption Notifications |
Keller and Heckman LLP |
Dec 3 2024 |
Can the President Impose Tariffs without Congressional Approval? |
Miller Canfield |
Dec 3 2024 |
APHIS Revises and Adds Exemptions for Plants Modified or Produced through Genetic Engineering |
Bergeson & Campbell, P.C. |
Dec 3 2024 |
NJ’s Mixed Smoke Signals: Cracking Down on Hemp but Stalling on Cannabis Lounges |
Norris McLaughlin P.A. |
Dec 3 2024 |
Latest updates on Per- and Polyfluorinated Substances (PFAS) in Europe |
Squire Patton Boggs (US) LLP |
Dec 2 2024 |
New York Enacts Laws to Enhance Restaurant Health and Safety Standards |
Greenberg Traurig, LLP |
Dec 2 2024 |
Federal Court Rules That Illegal Acts Are Legal Because They Are Illegal: Cannabis Law in a Nutshell |
Bradley Arant Boult Cummings LLP |
Dec 2 2024 |
Navigating Regulatory Challenges in the Dietary Supplement Industry: Insights on NJ Assembly Bill No. 1848 |
Epstein Becker & Green, P.C. |
Dec 2 2024 |
GLP-1 Drugs: Brand Companies Push FDA to Limit Compounding |
Foley & Lardner LLP |
Dec 2 2024 |
FDA Commissioner Califf Calls for Better Research and Action on Ultra-Processed Foods |
Keller and Heckman LLP |
Nov 27 2024 |
FDA Affirms Its Decision to Remove 25 Plasticizers From the Food Additive Regulations |
K&L Gates LLP |
Nov 27 2024 |
Take a Sad Song and Make It Better: Fifth Circuit’s Commercial Speech Ruling Leaves Door Open to State Law Challenge |
Bradley Arant Boult Cummings LLP |
Nov 27 2024 |
Briefing Continues in Lawsuit Targeting Florida Cultivated Meat Ban |
Keller and Heckman LLP |
Nov 27 2024 |
Relaxation of Long-Standing Restrictions on Foreign Investment in the Healthcare Sector in China |
McDermott Will & Emery |
Nov 26 2024 |
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescriptions of Controlled Medications |
Norris McLaughlin P.A. |
Nov 26 2024 |
9th Circuit Finds ‘Fruit Naturals’ Label Not Deceptive |
Keller and Heckman LLP |
Nov 26 2024 |
New Jersey General Assembly Passes Legislation Prohibiting Sale of Diet Pills, Weight Loss/Muscle Building Supplements to Minors |
Epstein Becker & Green, P.C. |
Nov 25 2024 |
Putting the Uniformity Back in the Uniform Trade Secrets Act: Sixth Circuit Rules Breach of Contract Claims Can Still Be Used to Protect Trade Secrets |
Foley & Lardner LLP |
Nov 23 2024 |
FDA Extends Comment Deadline for Proposed Post-Market Assessment Approach |
Keller and Heckman LLP |
Nov 22 2024 |
EPA Releases Updates to Suggested Pesticide Benefits Information Submittals |
Bergeson & Campbell, P.C. |
Nov 22 2024 |
McDermott+ Check-Up: November 22, 2024 |
McDermott Will & Emery |
Nov 22 2024 |
Gaetz Out as Possible Attorney General, Pam Bondi New Nominee: A Discussion Still Limited to Cannabis Implications |
Bradley Arant Boult Cummings LLP |